Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.78 |
| ▸ | HPN | P05981 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.78 |
| ▸ | VCAM1 | P19320 | 13/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Probucol SCHEMBL5143451 | 0.88 | HPN (1.00) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL4150 | 0.88 | HPN (1.00) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL6439618 | 0.86 | HPN (0.62) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL4620631 | 0.86 | ALOX15 (0.95) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL8344652 | 0.86 | ALOX15 (0.95) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL9240897 | 0.86 | HPN (0.52) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL4985953 | 0.85 | HPN (0.84) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL6361160 | 0.82 | ALOX15 (0.62) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL12791592 | 0.81 | ALOX15 (0.84) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL8344272 | 0.79 | HPN (0.81) | ALOX15HPNMAPTSIRT5VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023102613-A1 | BILE ACID CONJUGATE | CURTIN UNIVERSITY (AU) | 2023-06-15 | — | — | WO | claimed |
| WO-2023102613-A1 | BILE ACID CONJUGATE | CURTIN UNIVERSITY (AU) | 2023-06-15 | — | — | WO | disclosed |
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2008-09-04 | — | — | US | disclosed |
| US-7375252-B2 | Compounds and method for the inhibition of the expression of VCAM-1 | ATHEROGENICS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7189870-B2 | Compounds and methods for the inhibition of the expression of VCAM-1 | ATHEROGENIC, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1726582-A2 | Compounds and methods for the inhibition of the expression of vcam-1 | Atherogenics, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1695959-A1 | Compouds and methods for the inhibition of the expression of VCAM-1 | Atherogenics, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20050090487-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | ATHEROGENICS, INC. | 2005-04-28 | — | — | US | disclosed |
| US-20050065121-A1 | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters | SIKORSKI JAMES A (US) | 2005-03-24 | — | — | US | disclosed |
| US-6828447-B2 | Therapeutic agent for use in the treatment of cardiovascular and inflammatory disorders | ATHEROGENICS, INC. | 2004-12-07 | — | — | US | disclosed |
| US-6617352-B2 | Cardiovascular disorders; antiinflammatory agents | ATHEROGENICS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-6602914-B2 | Treatment of a disease that is mediated by the expression or suppression of a redox sensitive gene, for example MCP-1, IL-6 and thrombin receptor; antiinflammatory agents; cardio-vascular disorders; atherosclerosis; immunology | ATHEROGENICS, INC. | 2003-08-05 | — | — | US | disclosed |
| US-6548699-B1 | 4,4*-(Isopropylidenedithio)-(2*,6*-di-tert-butylphenol)-(2,6-d i-tert-butylphenol-O*-acetic acid); antiarthritic, antiinflammatory agents; rheumatic and cardiovascular disorders | ATHEROGENICS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20030064967-A1 | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters | ATHEROGENICS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20020188118-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2002-12-12 | — | — | US | disclosed |
| US-20020169215-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | CRABTREE ACQUISITION CO, LLC | 2002-11-14 | — | — | US | disclosed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-6147250-A | TREATING DISEASES MEDIATED BY VASCULAR CELL ADHESION MOLECULE-1, INCLUDING CARDIOVASCULAR AND INFLAMMATORY DISEASES; SUCCINOBUCOL | ATHEROGENICS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0994853-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | Atherogenics, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998051662-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF VCAM-1 | ATHEROGENICS, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169215-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | VCAM1, ICAM1, SELL | ALOX15 237/4885HPN 900/4885MAPT 3002/4885 |
| US-20050065121-A1 | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters | HDLBP, CETP, APOB | ALOX15 2135/4885HPN 167/4885MAPT 3773/4885 |
| US-20030064967-A1 | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters | HDLBP, CETP, APOB | ALOX15 2135/4885HPN 167/4885MAPT 3773/4885 |
| US-20080214660-A1 | Compounds and Methods for the Inhibition of the Expression of VCAM-1 | VCAM1, ICAM1, SELL | ALOX15 237/4885HPN 900/4885MAPT 3002/4885 |
| US-20020188118-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | VCAM1, ICAM1, SELL | ALOX15 237/4885HPN 900/4885MAPT 3002/4885 |
| US-20050090487-A1 | Compounds and methods for the inhibition of the expression of VCAM-1 | VCAM1, ICAM1, SELL | ALOX15 237/4885HPN 900/4885MAPT 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.